RxDoctor Payments DataLook up a doctor →

Hetty Carraway, MD

Hematology & Oncology · Chagrin Falls, OHNPI 1457319717

Payments from drug & device makers

$1,576,054in general payments, 2019–2025

Across 419 payments — averaging $3761.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$351K
  • Bristol Myers Squibb$254K
  • AbbVie$172K
  • Novartis$138K
  • Takeda Pharmaceuticals U.S.A., Inc.$129K
  • Rigel Pharmaceuticals, Inc.$120K
  • plus $412K from 19 others
$228,417in research payments, 2019–2025

Across 28 payments — averaging $8157.76 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$167K
  • Takeda Pharmaceuticals U.S.A., Inc.$62K

What the payments were for

  • Consulting fees$204,51449%
  • Speaking & faculty fees$184,48344%
  • Travel & lodging$19,3315%
  • Food & beverage$7,1512%
  • Education$1490%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,576,054 in reported general payments places this provider in the 90th percentile of 450 hematology & oncology providers in Ohio.

See all hematology & oncology providers in Ohio

Medicare billing

Part B allowed, 2024
$38,332
Medicare patients
76
Services billed
309

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TibsovoIvosidenib17$567,260
RydaptMidostaurin11$234,522
RevlimidLenalidomide12$211,233
TasignaNilotinib Hcl13$127,451
VenclextaVenetoclax24$20,612
Acyclovir69$1,024
Ondansetron Hcl14$226
Levofloxacin21$110
Prednisone13$99
Allopurinol33$76

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Servier Pharmaceuticals LLCTibsovo$14,565$567,26017 claims
NovartisRydapt, Tasigna$137,848$361,97424 claims
Bristol Myers SquibbRevlimid$253,800$211,23312 claims
AbbVieVenclexta$171,973$20,61224 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 450 hematology & oncology providers in Ohio.

Other hematology & oncology in Chagrin Falls

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →